You are here

ASCO 2010- Abstracts from the yearly meeting of the American Society of Clinical Oncology

sandy craine's picture
Submitted by sandy craine on Fri, 28/05/2010 - 1:28pm

Imatinib 800 mg Associated With Faster MMR vs Imatinib 400 mg or Imatinib 400 mg Plus Interferon in Previously Untreated Chronic-Phase CML.  June 11, 2010- German CML Study IV: randomized, treatment optimization trial......

Imatinib 800 mg Associated With Faster MMR vs Imatinib 400 mg or Imatinib 400 mg Plus Interferon in Previously Untreated Chronic-Phase CML.  June 11, 2010- German CML Study IV: randomized, treatment optimization trial......

Functional Activity of the OCT-1 Protein Is Predictive of Long-Term Outcome in Patients With Chronic-Phase Chronic Myeloid Leukemia Treated With Imatinib J Clin Oncol. 2010 Apr 26;

sandy craine's picture
Submitted by sandy craine on Tue, 18/05/2010 - 11:13am
Functional Activity of the OCT-1 Protein Is Predictive of Long-Term Outcome in Patients With Chronic-Phase Chronic Myeloid Leukemia Treated With Imatinib J Clin Oncol. 2010 Apr 26; Epub ahead of print, DL White, P Dang, J Engler, A Frede, S Zrim, M Osborn, VA Saunders, PW Manley, TP Hughes

Functional Activity of the OCT-1 Protein Is Predictive of Long-Term Outcome in Patients With Chronic-Phase Chronic Myeloid Leukemia Treated With Imatinib
J Clin Oncol. 2010 Apr 26; Epub ahead of print, DL White, P Dang, J Engler, A Frede, S Zrim, M Osborn, VA Saunders, PW Manley, TP Hughes

WT1 PEPTIDE VACCINATION IN COMBINATION WITH IMATINIB THERAPY FOR A PATIENT WITH CML IN THE CHRONIC PHASE

sandy craine's picture
Submitted by sandy craine on Wed, 05/05/2010 - 11:11am
Abstract Although tyrosine kinase inhibitors is effective for dramatically reducing CML cells, it might be difficult to eradicate completely the CML stem cells. We aimed to clarify the safety and effects of WT1 peptide vaccination in combination with imatinib therapy for a CML patient. A 51 year-old male with CML in CP, who showed a resistance against imatinib therapy for 2.5 years, began to be treated with 9mer modified-type WT1 peptides in combination with standard dose of imatinib. Although every 2-week-administration of WT1 peptides for 22 weeks did not show definite effects on the quantification of bcr-abl transcripts, by changing the administration from every 2 weeks to 4 weeks bcr-abl transcripts decreased remarkably. After 11 months of every 4-week-administration of the peptides and 12 months post cessation of the peptides bcr-abl transcripts achieved to the level below detection by RQ/RT-PCR (complete molecular response). WT1/MHC tetramer+CD8+ CTLs, which appeared after the second administration of WT1 peptides and remained more than 15 in number among 106 CD8+ T cells throughout the administration of WT1 peptides, are still present in the blood on 14th month post cessation of the peptides. An in vitro study as to the cytotoxicity of lymphocytes induced by mixed lymphocyte peptide culture demonstrated that cultured lymphocytes possessed cytotoxicity against WT1 expressing leukemia cells and the cytotoxicity was WT1-specific and MHC class I restricted. The present study showed that WT1 peptide vaccination in combination with TKI is feasible and effective in the therapy for imatinib-resistant CML.

Abstract
Although tyrosine kinase inhibitors is effective for dramatically reducing CML cells, it might be difficult to eradicate completely the CML stem cells. We aimed to clarify the safety and effects of WT1 peptide vaccination in combination with imatinib therapy for a CML patient. A 51 year-old male with CML in CP, who showed a resistance against imatinib therapy for 2.5 years, began to be treated with 9mer modified-type WT1 peptides in combination with standard dose of imatinib. Although every 2-week-administration of WT1 peptides for 22 weeks did not show definite effects on the quantification of bcr-abl transcripts, by changing the administration from every 2 weeks to 4 weeks bcr-abl transcripts decreased remarkably. After 11 months of every 4-week-administration of the peptides and 12 months post cessation of the peptides bcr-abl transcripts achieved to the level below detection by RQ/RT-PCR (complete molecular response). WT1/MHC tetramer+CD8+ CTLs, which appeared after the second administration of WT1 peptides and remained more than 15 in number among 106 CD8+ T cells throughout the administration of WT1 peptides, are still present in the blood on 14th month post cessation of the peptides. An in vitro study as to the cytotoxicity of lymphocytes induced by mixed lymphocyte peptide culture demonstrated that cultured lymphocytes possessed cytotoxicity against WT1 expressing leukemia cells and the cytotoxicity was WT1-specific and MHC class I restricted. The present study showed that WT1 peptide vaccination in combination with TKI is feasible and effective in the therapy for imatinib-resistant CML.

Welcome to CMLSupport.org.uk - please sign our petition!

admin's picture
Submitted by admin on Mon, 05/04/2010 - 10:31pm

GoPetition  The CML Support Group says: ”Patients are angry, frightened and very frustrated by this inhumane provisional recommendation by the NICE appraisal committee- a recommendation that seems to us to have much more to do with cost cutting than with a rational appraisal of two highly effective and innovative therapies. If the recommendation is upheld, and NHS funding of these therapies is refused in cases of imatinib intolerance, it will undoubtedly cost lives. It is a shocking prospect that UK citizens, who prove to be intolerant to standard dose imatinib (Glivec) will be denied access to such effective and life-saving alternatives. Clinicians will find themselves unable to treat their patients within internationally agreed expert recommendations outlined by the European Leukaemia Network, with the knowledge that clinicians in Germany, France, the Netherlands and other EU countries, are able to offer their patients the very best therapeutic options available.

<p>
<a class="topleft" href="http://www.gopetition.com/petitions/be-nice-to-cancer-patients/sign.html... alt="GoPetition" src="http://www.gopetition.com/counters?pid=34249&amp;t=2" title="NICE: Be NICE to Cancer Patients (powered by GoPetition)" width="206" /></a>&nbsp; The CML Support Group says: &rdquo;Patients are angry, frightened and very frustrated by this inhumane provisional recommendation by the NICE appraisal committee- a recommendation that seems to us to have much more to do with cost cutting than with a rational appraisal of two highly effective and innovative therapies. If the recommendation is upheld, and NHS funding of these therapies is refused in cases of imatinib intolerance, it will undoubtedly cost lives. It is a shocking prospect that UK citizens, who prove to be intolerant to standard dose imatinib (Glivec) will be denied access to such effective and life-saving alternatives. Clinicians will find themselves unable to treat their patients within internationally agreed expert recommendations outlined by the European Leukaemia Network, with the knowledge that clinicians in Germany, France, the Netherlands and other EU countries, are able to offer their patients the very best therapeutic options available.</p>

FDA- rules against targeted therapy because 'standarized' mutation test is not available.

sandy craine's picture
Submitted by sandy craine on Sun, 28/03/2010 - 4:08pm
FDA Committee Favors Validated Gene Test Before Considering Targeted Therapy Elsevier Global Medical News. 2010 Mar 22, K Wachter

FDA Committee Favors Validated Gene Test Before Considering Targeted Therapy
Elsevier Global Medical News. 2010 Mar 22, K Wachter

DailyMail article- "NICE rejects cancer drugs..."

sandy craine's picture
Submitted by sandy craine on Tue, 16/03/2010 - 11:47am
Betrayal of 20,000 cancer patients: Rationing body rejects ten drugs (allowed in Europe) that could have extended lives By DANIEL MARTIN
Last updated at 12:10 AM on 16th March 2010
www.dailymail.co.uk/health/article-1257944/NICE-rejects-cancer-drugs-extended-patients-lives

Betrayal of 20,000 cancer patients: Rationing body rejects ten drugs (allowed in Europe) that could have extended lives
By DANIEL MARTIN


Last updated at 12:10 AM on 16th March 2010


www.dailymail.co.uk/health/article-1257944/NICE-rejects-cancer-drugs-extended-patients-lives

Ohio State University Researchers identify Key Cause of Chronic Leukaemia Progression

sandy craine's picture
Submitted by sandy craine on Fri, 05/03/2010 - 6:16pm
Cancer Issues Author: Ohio State University Comprehensive Cancer Center Last Updated: Mar 4, 2010 - 4:43:44 PM Key Cause of Chronic Leukemia Progression By Ohio State University Comprehensive Cancer Center Mar 4, 2010 - 4:39:45 PM (HealthNewsDigest.com) - COLUMBUS, Ohio – Researchers have discovered a key reason why a form of leukemia progresses from its more-treatable chronic phase to a life-threatening phase called blast crisis.

Cancer Issues Author: Ohio State University Comprehensive Cancer Center Last Updated: Mar 4, 2010 - 4:43:44 PM

Key Cause of Chronic Leukemia Progression

By Ohio State University Comprehensive Cancer Center
Mar 4, 2010 - 4:39:45 PM

(HealthNewsDigest.com) - COLUMBUS, Ohio – Researchers have discovered a key reason why a form of leukemia progresses from its more-treatable chronic phase to a life-threatening phase called blast crisis.

Pages